Come and find out what we have in the pipeline and explore those indications where our technology is set to have the greatest clinical benefit.
Home - Pipeline
What's in the pipeline?
Indication
Short Description
Pre-clinical discovery
Pre-clinical development
Phase I/IIa
Phase IIb
Phase III
Status
Active ingredient
Mechanism
Recessive dystrophic epidermolysis bullosa (RDEB) a b d
Genetic disorder with systemic inflammation and severe wounds, reduced life expectancy
In set up
allo-APZ2 1
Anti-inflammation
Non-healing chronic venous wounds (CVU) 4 5
Non-healing wound from venous insufficiency
Recruiting
allo-APZ2 1
Anti-inflammation
Non-healing diabetic foot ulcers (DFU)
Non-healing wound as diabetic complication
In set up
allo-APZ2 1
Anti-inflammation
Limbal stem cell deficiency (LSCD) a b c
A lack of LSCs leading to LSCD, potential blindness
On hold
LSC2 3
Regeneration
Acute graft-versus-host disease (GvHD)
Severe immune response caused by bone-marrow transplant, potential fatal
Ongoing
allo-APZ2 1
Anti-inflammation
Polycystic kidney disease (PKD)
Genetic disorder resulting in renal failure with potential fatal outcome
Ongoing
allo-APZ2 1
Anti-inflammation and Regeneration
Transplant rejection
Complication caused by immune-system overreaction
Ongoing
allo-APZ2 1
Anti-inflammation
Non-healing chronic venous wounds (CVU)
Non-healing wound from venous insufficiency
Closed
APZ2 2
Anti-inflammation
1 Allogeneic ABCB5-positive mesenchymal stem cells
2 Autologous ABCB5-positive mesenchymal stem cells
3 Allogeneic ABCB5-positive limbal stem cells
4 Marketing authorization in Germany granted for AMESANAR®
5 RHEACELL's cell therapy product AMESANAR® is now listed on the website of Germany's Federal Institute for Vaccines and Biomedicines (competent authority)
a Orphan Drug Designation FDA
b Orphan Drug Designation EMA
c Fast Track Designation FDA
d Pediatric Investigation Plan (PIP) approved by PDCO (EMA)